COVID-19 Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0HN8P
|
|||
Drug Name |
Leronlimab
|
|||
Synonyms |
PRO 140
|
|||
Drug Type |
Monoclonal antibody
|
|||
Indication | Coronavirus Disease 2019 (COVID-19) | Phase 2 | [1], [2] | |
Therapeutic Class |
Antiviral Agents
|
|||
PubChem Substance ID |
Target | Top | |||
---|---|---|---|---|
Target(s) | HUMAN C-C chemokine receptor 5 (CCR5) | Target Info | Inhibitor | [3] |
Disrupting the CCL5-CCR5 axis via leronlimab-mediated CCR5 blockade can prevent pulmonary trafficking of proinflammatory leukocytes and reverse cytokine storm in COVID-19. |
References | Top | |||
---|---|---|---|---|
1 | ClinicalTrials.gov (NCT04343651) Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19 | |||
2 | Leronlimab Shows Further Promise for COVID-19 Treatment, Study Shows. May 09, 2020 | |||
3 | Disruption of the CCL5/RANTES-CCR5 Pathway Restores Immune Homeostasis and Reduces Plasma Viral Load in Critical COVID-19 |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.